News & Resources | TB Alliance

Latest News

October 28

TB Alliance Welcomes Global Drug Facility’s Listing of Pretomanid

October 28

TB Alliance and Macleods Announce Commercial Partnership for New Therapy for Highly Drug-Resistant TB

October 17

With One and a Half Million People Dying from TB Every Year, It’s Time to Accelerate Progress

Voices of TB

Videos from the Global Health Community

Kenya Launches Child-Friendly TB Medicine

New Childhood TB Medicines Will Help Save Lives

Featured Publication

Accessing Improved TB Medicines for Children

Click here to download the full report

Research Papers

Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial

An Assessment of Global Chemistry, Manufacturing and Controls (CMC) Regulatory Requirements in Low and Middle Income Countries

Gender differences in tuberculosis treatment outcomes: a post hoc analysis of the REMox TB study

For the Press

Press Contact:
Thomas Lynch
p | +1 646 616 8639
e | thomas.lynch@tballiance.org

View the Annual Report 2018